Company news
Bone Biologics Corp (NASDAQ:BBLG) news
Bone Biologics Corp news releases on 6ix. Latest, Sep 8, 2026: Bone Biologics Expands Trial Sites
Press releases & updates
Bone Biologics Expands Trial Sites
September 8, 2026
Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
September 3, 2026
Bone Biologics Achieves 32-Month Validated Shelf Life for rhNELL-1
August 12, 2026
Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities
July 23, 2026
Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
July 6, 2026
Bone Biologics Achieves 29-Month Validated Shelf Life for rhNELL-1
May 18, 2026
Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook
January 8, 2026
Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
December 23, 2025
Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook
September 4, 2025
Bone Biologics to Participate in the H.C. Wainwright Global Investment Conference
September 3, 2025
Bone Biologics Announces Closing of $5.0 Million Public Offering
June 30, 2025
Bone Biologics Announces Pricing of $5.0 Million Public Offering
June 27, 2025
Bone Biologics Files Patent Application for Bone Regeneration Technology
June 27, 2025
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
June 26, 2025
Bone Biologics Announces 1-for-6 Reverse Stock Split
June 6, 2025
Bone Biologics Appoints Phillip T. Meikle to its Board of Directors
October 20, 2024
Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds
August 1, 2024
First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion
June 19, 2024
Bone Biologics Announces Closing of $2.0 Million Public Offering
March 6, 2024
Bone Biologics Announces Pricing of $2.0 Million Public Offering
March 3, 2024
Bone Biologics Reports Progress With NB1 Clinical Program
February 29, 2024
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
January 10, 2024
Bone Biologics Announces 1-for-8 Reverse Stock Split
December 17, 2023
Bone Biologics Announces Closing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 20, 2023
Bone Biologics Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
November 15, 2023
Bone Biologics Provides Scientific Update on NB1 Bone Graft Device
September 25, 2023
Bone Biologics Prices $5.0 Million Underwritten Public Offering
June 13, 2023
Bone Biologics Effects 1-for-30 Reverse Stock Split
June 5, 2023
Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia
April 10, 2023
Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization
January 25, 2023
Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering
October 11, 2022
CORRECTING and REPLACING Bone Biologics Prices $5,100,000 Underwritten Public Offering
October 6, 2022
Bone Biologics Enters into Supply Agreement with MTF Biologics for Demineralized Bone Matrix
March 6, 2022
Bone Biologics Corp. Announces Closing of Public Offering and Uplisting to Nasdaq
October 17, 2021
Bone Biologics Corp. Announces Pricing of $7.9 million Public Offering; Uplisting to the Nasdaq Capital Market and Reverse Stock Split
October 12, 2021
Bone Biologics Preclinical Study Shows rhNELL-1 Effectively Promotes Bone Formation
January 6, 2020